NO162069B - Analogifremgangsm te for fremstilling av 1h-indol-3-yl inneholdende 1,3-di-metyl-1h-purin-2,6-dioner. - Google Patents
Analogifremgangsm te for fremstilling av 1h-indol-3-yl inneholdende 1,3-di-metyl-1h-purin-2,6-dioner. Download PDFInfo
- Publication number
- NO162069B NO162069B NO853856A NO853856A NO162069B NO 162069 B NO162069 B NO 162069B NO 853856 A NO853856 A NO 853856A NO 853856 A NO853856 A NO 853856A NO 162069 B NO162069 B NO 162069B
- Authority
- NO
- Norway
- Prior art keywords
- dione
- indol
- purine
- dimethyl
- dihydro
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 9
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 title claims abstract description 6
- -1 1H-INDOL-3-YL Chemical class 0.000 title description 7
- 239000002253 acid Substances 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims abstract description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 7
- OJOSYHJYEWUYGU-UHFFFAOYSA-N 7-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=CC=C2C(C3CCN(CC3)CCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 OJOSYHJYEWUYGU-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 150000003053 piperidines Chemical class 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 3
- 230000002539 anti-aggressive effect Effects 0.000 abstract description 2
- 230000002180 anti-stress Effects 0.000 abstract description 2
- 239000002249 anxiolytic agent Substances 0.000 abstract description 2
- 230000000949 anxiolytic effect Effects 0.000 abstract description 2
- 230000001624 sedative effect Effects 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 229960002748 norepinephrine Drugs 0.000 description 7
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 6
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 6
- 229960004046 apomorphine Drugs 0.000 description 6
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 6
- 229960001701 chloroform Drugs 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- QCIARNIKNKKHFH-UHFFFAOYSA-N 7-(2-chloroethyl)-1,3-dimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CCCl)C=N2 QCIARNIKNKKHFH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- KAIRZPVWWIMPFT-UHFFFAOYSA-N 3-piperidin-4-yl-1h-indole Chemical compound C1CNCCC1C1=CNC2=CC=CC=C12 KAIRZPVWWIMPFT-UHFFFAOYSA-N 0.000 description 2
- ZDYHRRFHPRZGRR-UHFFFAOYSA-N 7-(3-chloropropyl)-1,3-dimethylpurine-2,6-dione;hydrochloride Chemical compound Cl.O=C1N(C)C(=O)N(C)C2=C1N(CCCCl)C=N2 ZDYHRRFHPRZGRR-UHFFFAOYSA-N 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
- OSJHJNMMVGKXKP-UHFFFAOYSA-N 1,3-dimethyl-7-[2-[4-(7-methyl-1h-indol-3-yl)piperidin-1-yl]ethyl]purine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCN(CC1)CCC1C1=CNC2=C1C=CC=C2C OSJHJNMMVGKXKP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- ALNXBNRDOANKRI-UHFFFAOYSA-N 3-(3,6-dihydro-2h-pyridin-1-yl)-1h-indole Chemical compound C1C=CCCN1C1=CNC2=CC=CC=C12 ALNXBNRDOANKRI-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XOYQYCDKGORDBS-UHFFFAOYSA-N 3-piperidin-4-yl-1h-indol-5-ol Chemical compound C12=CC(O)=CC=C2NC=C1C1CCNCC1 XOYQYCDKGORDBS-UHFFFAOYSA-N 0.000 description 1
- FCKKUEPMSPRIAO-UHFFFAOYSA-N 5-bromo-3-(1,2,3,6-tetrahydropyridin-4-yl)-1h-indole Chemical compound C12=CC(Br)=CC=C2NC=C1C1=CCNCC1 FCKKUEPMSPRIAO-UHFFFAOYSA-N 0.000 description 1
- NAMXAGZUVLXVPK-UHFFFAOYSA-N 7-[2-[4-(1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=CC=C2C(C=3CCN(CC=3)CCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 NAMXAGZUVLXVPK-UHFFFAOYSA-N 0.000 description 1
- FQSFRYMUMFPRGN-UHFFFAOYSA-N 7-[2-[4-(1h-indol-3-yl)piperidin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione;hydrochloride Chemical compound Cl.C1=CC=C2C(C3CCN(CC3)CCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 FQSFRYMUMFPRGN-UHFFFAOYSA-N 0.000 description 1
- WOHDAIYKWKNOGQ-UHFFFAOYSA-N 7-[2-[4-(5-bromo-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione;hydrochloride Chemical compound Cl.C1=C(Br)C=C2C(C=3CCN(CC=3)CCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 WOHDAIYKWKNOGQ-UHFFFAOYSA-N 0.000 description 1
- ZLNPNFODBYKLSJ-UHFFFAOYSA-N 7-[2-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=C(Cl)C=C2C(C3CCN(CC3)CCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 ZLNPNFODBYKLSJ-UHFFFAOYSA-N 0.000 description 1
- PDFWVEXNHSBEAZ-UHFFFAOYSA-N 7-[2-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=C(F)C=C2C(C3CCN(CC3)CCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 PDFWVEXNHSBEAZ-UHFFFAOYSA-N 0.000 description 1
- OCIGEVWGDSVNTO-UHFFFAOYSA-N 7-[3-[4-(1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=CC=C2C(C=3CCN(CC=3)CCCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 OCIGEVWGDSVNTO-UHFFFAOYSA-N 0.000 description 1
- BSTZLLNYYJASEW-UHFFFAOYSA-N 7-[3-[4-(5-bromo-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=C(Br)C=C2C(C=3CCN(CC=3)CCCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 BSTZLLNYYJASEW-UHFFFAOYSA-N 0.000 description 1
- WNGLJOPEYUIVEM-UHFFFAOYSA-N 7-[3-[4-(5-methoxy-1h-indol-3-yl)piperidin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCCN(CC1)CCC1C1=CNC2=CC=C(OC)C=C21 WNGLJOPEYUIVEM-UHFFFAOYSA-N 0.000 description 1
- NYENFKILUZEINJ-UHFFFAOYSA-N 7-[3-[4-(6-fluoro-1h-indol-3-yl)piperidin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound FC1=CC=C2C(C3CCN(CC3)CCCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 NYENFKILUZEINJ-UHFFFAOYSA-N 0.000 description 1
- KYEVGHAGJZAHEB-UHFFFAOYSA-N 7-[4-[4-(1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]butyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=CC=C2C(C=3CCN(CC=3)CCCCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 KYEVGHAGJZAHEB-UHFFFAOYSA-N 0.000 description 1
- RPIZNTPITLJJRK-UHFFFAOYSA-N 7-[4-[4-(6-fluoro-1h-indol-3-yl)piperidin-1-yl]butyl]-1,3-dimethylpurine-2,6-dione Chemical compound FC1=CC=C2C(C3CCN(CC3)CCCCN3C=NC=4N(C(N(C)C(=O)C=43)=O)C)=CNC2=C1 RPIZNTPITLJJRK-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- OKIBNKKYNPBDRS-UHFFFAOYSA-N Mefluidide Chemical compound CC(=O)NC1=CC(NS(=O)(=O)C(F)(F)F)=C(C)C=C1C OKIBNKKYNPBDRS-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 229960003990 apomorphine hydrochloride Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Description
I EP-PS 71 738 er det beskrevet et antall piperidiner og piperaziner inneholdende teofyllinderivater som forbindelser med forskjellige farmakologiske egenskaper. Videre er et antall 4-]lH-indol-3-yl-piperidiner beskrevet i US-PS 3 980 658 og 3 947 578 som forbindelser som kan brukes som beroligende midler henholdsvis som neuroleptika, og i US-PS 4 359 468 og 4 342 870 som antiallergika og hypotensive henholdsvis serotonin antagonister.
I det ovenfor angitte EP-PS 0071 738 ble forbindelsene beskrevet å ha histamin-, serotonin- og bradikinantagonis-tiske egenskaper, være istand til å redusere blodtrykket, å være antianafylaktiske og p<->adrenergiske stimulanter.
GB-PS 2 083 470 lærer på den annen side at benzhydryl-substituerte piperidinyl og piperazinyl alkylteofyliner har vasodilatorisk og analgetisk virkning. Slike forbindelser er videre sagt å være istand til å inhibere trombositaggregering og å ha CNS-, antihistamin-, antiastma- og hypotensiv virkning.
Forbindelsene ifølge oppfinnelsen skiller seg fra disse både strukturelt og ved den spesifikke farmakologiske profil, mere spesielt deres evne til å antagonisere apomorfin, tryptamin og spesielt norepinefrin.
Forbindelsene som fremstilles ifølge oppfinnelsen inneholder en 1,3-dimetyl-lH-purin-2,6-diondel inneholdende et lH-indol-3-yl substituert piperidin eller 3,6-dihydro-l(2H)-pyridin og ved de spesifikke farmakologiske egenskaper.
Foreliggende oppfinnelse angår således fremstilling av nye lH-indol-3-yl holdige 1,3-dimetyl-lH-purin-2,6-dioner som strukturelt representeres ved formelen
og farmasøytisk akseptable syreaddisjonssalter derav, hvori Alk er en toverdig lavere alkylrest;
R er hydrogen, lavere alkyl, halogen, lavere alkyloksy
eller hydroksy;
der den stiplede linje antyder at dobbeltbindingen mellom 3-og 4-karbonatomer i piperidinkjernen er eventuell.
I de foregående definisjoner er "halogen" generisk for fluor, klor, brom og iod, og "lavere alkyl" er ment å inkludere rette eller forgrenede mettede hydrokarbonrester med fra 1-6 karbonatomer som for eksempel metyl, etyl, 1-metyletyl, 1,1-dimetyletyl, propyl, butyl, pentyl eller heksyl.
De mest foretrukne forbindelser er valgt blant gruppen bestående av
7-[2-[4-(lH-indol-3-yl)-l-piperidinyl]etyl]-3,7-dihydro-l,3-dimetyl-lH-purin-2,6-dion og farmasøytisk akseptable syreaddisjonssalter derav.
Forbindelsene med formel (I) kan generelt fremstilles ved omsetning av et mellomprodukt med formel (II) med et piperidin med formel (III) ved å følge kjente alkvler 1 r\ aa- n- n0-sed<y>rer:
Fremgangsmåten gjennomføres ved å omsette mellomproduktet med formel (II) der Alk er som angitt ovenfor og W er en reaktiv avspaltbar gruppe og fortrinnsvis halogen, med et piperidin med formelen Alkyleringsreaksjonene gjennomføres hensiktsmessig i et inert organisk oppløsningsmiddel, for eksempel et aromatisk hydrokarbon som benzen, metylbenzen eller dimetylbenzen, en lavere alkanol som metanol, etanol eller 1-butanol, et keton som 2-propanon eller 4-metyl-2-pentanon; en eter som 1,4-dioksan, 1,1'-oksybisetan eller tetrahydrofuran; N,N-dimetylformamid (DMF); N,N-dimetylacetamid (DMA); nitrobenz-en; l-metyl-2-pyrrolidinon o.l. Tilsetning av en egnet base slik som for eksempel et alkalimetallkarbonat eller -hydrogenkarbonat, natriumhydrid eller en organisk base som N,N-dietyletanamin eller N-(1-metyletyl)-2-propanamin, kan benyttes for å fange opp syre som settes fri i løpet av reaksjonen. I enkelte tilfelle er tilsetning av et iodid-salt, fortrinnsvis et alkalimetalliodid, hensiktsmessig. Noe forhøyede temperaturer kan øke reaksjonshastigheten.
Reaksjonsproduktene kan isoleres fra reaksjonsblandingen og, hvis nødvendig, renses ytterligere ved kjente metoder.
Forbindelsene med formel (I) har basiske egenskaper og derfor kan de omdannes til de terapeutisk aktive ikke-toksiske syreaddisjonssaltformer ved behandling med egnede syrer, for eksempel uorganiske syrer som hydrogenhalogensyrer som saltsyre, hydrobromsyre og lignende, eller svovelsyre, salpetersyre eller fosforsyre, samt organiske syrer som eddik-, propan-, hydroksyeddik-, 2-hydroksy-propan-, 2-oxopropan, etandion-, propandion-, butandion, (Z)-2-buten-dion, (E)-2-butendion-, 2-hydroksybutandIon-, 2,3-dihydrok-sybutandion-, 2-hydroksy-l,2,3-propantrikarboksyl-, metansul-f on-, etansulfon-, benzensulfon-, 4-metylbenzen-sulfon-, cykloheksansulamin-, 2-hydroksybenzo-, 4-amino-2-hydroksybenzo-, og lignende syrer. Omvendt kan saltformen omdannes ved behandling med alkali i den frie baseform.
Mellomproduktene og utgangsstoffene kan fremstilles ved å følge kjente prosedyrer som for eksempel beskrevet i US-PS 4 064 255, 4 196 209 og i de som er nevnt ovenfor.
Forbindelsene med formel (I) og de farmasøytisk akseptable syreaddisjonssalter derav er potente antagonister av en serie neurotransmittorer og har derfor brukbare farmakologiske egenskaper.
For eksempel har forbindelsene med formel (I) og deres farma-søytisk akseptable syreaddisjonssalter apomorfin-, tryptamin-og norepinefrin antagonistisk virkning. Disse virkningene vises i den følgende prøveprosedyre som beskrives nedenfor og de eksperimentelle data slik disse er oppsummert i Tabell 1,
Den kombinerte apomorfin (APO)-, tryptamin (TRY)- og norepinefrin (NOR) prøve i rotter.
Forsøksdyrene som ble benyttet i denne prøve var voksne hann Vistar hannrotter med en kroppsvekt på 240+- 10g). Etter faste over natt ble dyrene behandlet subkutant med 1 ml/100 g av en vandig oppløsning av forbindelsen som skulle undersøkes (tid = null) og bragt i isolerte observasjonsbur. 30 minutter deretter (tid = 30 minutter) ble 1,25 mg/kg apomorfin hydroklorid, APO, injisert intravenøst og rottene observert i en 1 times periode på nærvær eller fravær av de følgende apomorfininduserte fenomener: agitering og sterotyp-lsk tygging. Ved slutten av denne 1 times periode (t = 90 min.) ble de samme dyr injisert intravenøst med 40 mg/kg tryptamin (TRY) og nærværet av typiske tryptamin-induserte bilatterale toniske kramper notert. To timer etter forbe-handling, t = 120 min., ble tilslutt de samme dyr utfordret med 1,25 mg/kg intravenøst av norepinefrin, NOR, og mulig dødelighet ble observert i ytterligere 60 minutter.
Tabell I gir EDsg-verdiene for et antall av forbindelsene som betraktes. Som brukt her representerer ED50 verdiene en dose som beskytter 50$ av dyrene fra apomorfin-, tryptamin- eller norepinefrin-induserte fenomener.
Forbindelsene som er angitt i Tabell 1 er kun gitt for å illustrere oppfinnelsen.
På grunn av de farmakologiske virkninger kan forbindelsene med formel (I) og deres farmasøytisk akseptable syreaddisjonssalter benyttes ved behandling av varmblodige dyr som lider av psykotrope sykdommer. De angjeldende forbindelser har også brukbare egenskaper som sedatering-, anxiolytiske, anti-agressive og anti-stressmidler og, som en konsekvens, er de brukbare for å beskytte ikke-humane varmblodige dyr, for eksempel I stress-stluasjoner som under transport og lignende. Mere spesielt kan oppfinnelsens forbindelser benytte for manipulering, større og mindre kirurgi, transport og gruppering av dyr.
EKSEMPLER
Eksempel 1
En blanding av 5 deler 7-(2-kloretyl)-3,7-dihydro-l,3-dimetyl-lH-purin-2,6-dion, 4 deler 4 deler 3-(4-piperdinyl)-lH-indol, 8 deler av natriumkarbonat, 1 del kaliumiodid og 120 deler 4-metyl-2-pentanon ble omrørt og kokt under tilbakeløp over natt. Reaksjonsblandingen ble avkjølt, vann ble tilsatt og sjiktene separert. Den organiske fase ble tørket, filtrert og fordampet. Resten ble renset ved kolonnekromatografi over silikagel ved bruk av triklormetanrmetanol i volumforholdet 95:5. De rene fraksjoner ble samlet og elueringsmidlet fordampet. Resten ble krystallisert fra 4-metyl-2-pentanon, hvorved man oppnådde 4 deler tilsvarende 50% 7-[2-[4-(lH-indol-3-yl)-l-piperidinyl]etyl]-3,7-dihydro-l,3-dimetyl-lH-purin-2,6-dion med smeltepunkt 201,2°C (forbindelse 1).
Eksempel 2
En blanding av 3,65 deler 7-(2-kloretyl)-3,7-dihydro-l,3-dimetyl-lH-purin-2,6-dion, 3 deler 3-(4-piperidinyl)-lH-indol-5-ol, 4,25 deler natriumkarbonat, 0,1 deler av kalium iodid og 200 deler 4-metyl-2-pentanon ble omrørt og kokt under tilbakeløp over natt. Det hele ble filtrert i varm tilstand og filtratet fordampet. Resten ble suspendert i 45 deler triklormetan og 2,4 deler metanol. Produktet ble filtrert av, vasket med 16 deler metanol og tørket og man oppnådde 2,5 deler (43#) 3,7-di-hydro-7-[2-[4-(5-hydroksy-lH-indol-3-yl)-l-pipeidinyl]etyl]-1,3-dlmetyl-lH-purin-2,6-dion; smeltepunkt 232,5'C (forbindelse 2).
På tilsvarende måte ble det også fremstilt: 3 , 7-dihydro-l, 3-dimetyl-7-[2-[4-( 7-metyl-lH-indol-3-yl )-l-piperidlnyl]etyl]-lH-purin-2,6-dion; smeltepunkt 200,2°C (forbindelse 3); 7-[3-[4-(5-fluor-lH-indol-3-yl)-1-piperdinyl]propyl]-3 ,7-dihydro-1,3-dimetyl)-lH-purin-2,6-dion (E)-2-butendioat (1:1) smeltepunkt 232,3°C (forbindelse 4); 7-[2-[4 - ( 5-f luor-lH-indol-3-yl)-l-piperdinyl]etyl]-3,7-dihydro-1,3-dimetyl-lH-purin-2,6-dion , smeltepunkt 168,4°C (forbindelse 5); 7-[3-4-(5-klor-lH-indol-3-yl)-1-piper idinyl]propyl]-3,7-dihydro-1,3-dimetyl-lH-purin-2,6-dion; smeltepunkt 105,8°C (forbindelse 6); 7-[2-[4 - ( 5-klor-lH-indol-3-yl)-1-piper idinyl]ety1]-3,7-dihydro-1,3-dimetyl-lH-purin-2,6-dion; smeltepunkt 225,CC (forbindelse 7); 3 ,7-dihydro-7-[2-[4-(5-metoksy-lH-indol-3-yl)-1-piperidinyl-]etyl]-l,3-dimetyl-lH-purin-2,6-dion; smeltepunkt 205,0°C (forbindelse 8);
3,7-dihydro-7-[3-[4-(5-metoksy-lH-indol-3-yl)-l-piperidinyl]-propyl]-1,3-dimetyl-lH-purin-2,6-dion; smeltepunkt 104,4°C (forbindelse 9);
3,7-dihydro-l,3-dimetyl-7-[3-[4-(7-metyl-lH-indol-3-yl)-l-piperidinyl]-propylq-lH-purin-2,6-dion (E)-2-butendioat(1:1); smeltepunkt 228,1°C (forbindelse 10);
7-[2-[4-(5-brom-lH^lndol-3-yl )-3,6-dihydro-l(2H)-pyridinyl-]etyl]-3,7-dihydro-l,3-dimetyl-lH-purin-2,6-dion monohydroklorid; smeltepunkt 258,9°C (forbindelse 11); og 7-[2-[4-(6-fluor-lH-indol-3-yl)-3,6-dihydro-l(2H)-pyridinyl-]etyl]-3,7-dihydro-l,3-dimetyl-lH-purin-2,6-dion; smeltepunkt 163,5°C (forbindelse 12).
Eksempel 3
En blanding av 4,5 deler 7-(3-klorpropyl)-3,7-dihydro-l,3-dimetyl-lH-purin-2,6-dion monohydroklorid, 3 deler 3-(4-piperidinyl)-lH-indol, 8 deler natriumkarbonat, 0,1 del natriumiodid og 240 deler 4-metyl-2-pentanon ble omrørt og kokt under tilbakeløp i 20 timer. Resten ble renset ved kolonnekromatografi over silicagel ved bruk av triklormetanrmetanol i volumforholdet 92:8. De rene fraksjoner ble samlet og elueringsmidlet fordampet. Resten ble omdannet til (E)-2-butandioatsaltet i 2-propanol. Saltet ble filtrert av og tørket og man oppnådde 3,9 deler (48#) 3,7-dihydro-7-[3-[4-(lH-indol-3-yl)-l-piperidinyl]-propyl]-l,3-dimetyl-lH-purin-2,6-dion (E)-2-butendioat (1:1); smeltepunkt 222,7°C (forbindelse 13).
På tilsvarende måte ble det også fremstilt: 7-[3-[4-(6-f luor-lH-indol-3-yl )-1-piperidinyl]propyl]-3 ,7-dihydro-l ,3-dimetyl-lH-purin-2 ,6-dion, smeltepunkt 128,0°C (forbindelse 14); 3 ,7-dihydro-7- [4-[4-( 1H-indold-3-yl)-l-plperidinyl]butyl]-1,3-dimetyl-lH-purin-2,6-dion (E)-2-butendioat(2:1); smeltepunkt 227,7"C (forbindelse 15); og
7-[4-[4-(6-fluor-lH-indol-3-yl)-1-piperidiny1]butyl]-3 ,7-dihydro-1,3-dimetyl-lH-purin-2,6-dion; smltepunkt 151,8°C (forbindelse 16).
Eksempel 4
En blanding av 5 deler 7-(3-klorpropyl)-3,7-dihydro-l,3-dimetyl-lH-purin-2,6-dionmonohydroklorid, 4 deler 3-(l,2,3,6-tetrahydro-4-pyrodinyl)-lH-indol, 8 deler natriumkarbonat og 240 deler 4-metyl-2-pentanon ble omrørt i 22 timer ved tilbakeløpstemperatur. Det hele ble omrørt til romtemperatur var nådd. Produktet ble filtrert av og omrørt i vann. Etter filtrering ble produktet vasket med vann og omrørt i vann og en ekvimolar mengde eddiksyre. Blandingen ble behandlet med ammoniumhydroksyd. Det utfelte produkt ble filtrert av, tørket med vann og omrørt i en blanding av acetonitril og 2-propoanol. Produktet ble filtrert av, vasket med acetonitril og tørket og man oppnådde 7 deler (98$) av 7-[3-[3,6-dihydro-4-(lH-Indol-3-yl )-l ( 2H)-pyrIdinyl]-propyl]-3,7-dihydro-l,3-dimetyl-lH-purin-2,6-dion, smeltepunkt 243,2°C (forbindelse 17).
På tilsvarende måte ble det også fremstilt: 7-[4-[3 ,6-dihydro-4-( 1H-indol-3-yl )-l(2H)-pyridinyl]butyl]-3,7-dihydro-l,3-dimetyl-lH-purin-2,6-dion; smeltepunkt 198,3°C (forbindelse 18); og
7-[4-[4-(5-fluor-lH-indol-3-yl)-1-piperidiny1]butyl]-3 ,7-dihydro-1,3-dimetyl-lH-purin-2,6-dion (E)-2-butendioat(1:1); smseltepunkt 210,6"C (forbindelse 19).
Eksempel 5
En blanding av 6 deler 7-(3-klorpropyl )-3,7-dihydro-3-dimetyl-lH-purin-2,6-dion monohydroklorid, 5 deler 5-bromo-3-(1,2,3,6-tetrahydro-4-pyridinyl)-lH-indol, monohydrat, 10 deler natriumkarbonat, 0,2 deler natriumiodid og 135 deler N.N-dimetyl-acetamid ble omrørt og kokt over natt ved 90° C. Reaksjonsblandingen ble fordampet til tørr tilstand. Resten ble omrørt i vann. Produktet ble ekstrahert med triklormetan. Ekstraktet ble tørket, filtrert og fordampet. Resten ble renset ved kolonnekromatografi og ved silicagel ved bruk av en blanding av triklormetan:metanol 90:10. De rene fraksjoner ble samlet og elueringsmidlet fordampet. Resten ble krystallisert fra acetonitril. Produktet ble filtrert av og tørket og man oppnådde 3,2 deler (36$) 7-[3-[4-(5-brom-lH-indol-3-yl )-3,6-dihydro-l(2H)-pyridinyl]propyl]-3,7-dihydro-1,3-dimetyl-lH-purin-2,6-dion; smeltepunkt 195,1°C
(forbindelse 20).
Eksempel 6
En blanding av 3,8 deler 7-(2-kloretyl)-3,7-dihydro-l,3-dimetyl-lH-purin-2,6-dion, 3 deler 3-(3,6-dihydro-l(2H)-pyridinyl)-lH-indol, 8 deler natrium karbonat, 0,1 deler kaliumiodid og 270 deler metylbenzen ble omrørt og kokt under tilbakeløp i 20 timer. Reaksjonsblandingen ble filtrert i varm tilstand og filtratet fordampet. Resten ble renset ved kolonnekromatografi over silicagel ved bruk av triklormetan:metanol i volumforholdet 92:8. De rene fraksjoner ble samlet og elueringsmidlet fordampet. Resten ble krystallisert fra 2-propanon. Produktet ble filtrert av og tørket i vakuum ved 120°C og man oppnådde 3,1 deler (51, b%) 3,7-dihydro-7-[2-[3,6-dihydro-4-(lH-indol-3-yl)-l(2H)-pyridinyl]etyl]-l,3-dimetyl-lH-purin-2,6-dion; smeltepunkt 196,5'C (forbindelse 21).
Eksempel 7
En blanding av 5 deler 3,7-dihydro-7-[2-[4-(lH-indol-3-yl)-l-piperdinyl]etyl]-1,3-dimetyl-lH-purin-2,6-dion, 16 deler 2-propanol og 160 deler 2-propanol, mettet med gassformig hydrogenklorid, ble omrørt I 1 time ved 70°C. Etter avkjøling til 20° C ble produktet filtrert av, vasket to ganger med 24 deler acetonitril og tørket hvorved man oppnådde 4,3 deler (79%) 3,7-dihydro-7-[2-[4-(lH-indol-3-yl)-l-piperdinyl]etyl]-1,3-dimetyl-lH-purin-2,6-dion monohydroklorid; smeltepunkt 273,0"C. (forbindelse 22).
Eksempel 8
Til en omrørt blanding av 5 deler 3,7-dihydro-7-[2[4-(1H-indol-3-yl)-l-piperidinyl]etyl]-1,3-dimetyl-lH-purin-2,6-dion og 100 deler 2-metoksyetanol ble det tilsatt 3 deler av en 85% fosforsyre oppløsning. Etter omrøring I 30 minutter ble produktet filtrert av, vasket med 40 deler metanol og krystallisert fra 90 deler N,N-dimetylformamid ved 0°C. Produktet ble filtrert av, vasket med 16 deler metanol og tørket og man oppnådde 3,4 deler (57%) 3,7-dihydro-7-[2-<4->
(lH-indol-3-yl)-1-piperidinyl]etyl]-1,3-dimetyl-lH-purin-2,6-dion fosfat (1:1), smeltepunkt 254,7°C. (forbindelse 23).
Ved å følge den smame prosedyre og ved å benytte de egnede syrer ble det også fremstilt: 3,7-dihydro-7-[2-[4-(lH-indol-3-yl )-l-pipeidinyl]etyl]-1,3-dimetyl-lH-purin-2,6-dion sulfat (1:1); smeltepunkt 253,7°C, (forbindelse 24). 3 , 7-dihydro-7 - [2-4-( lH-indol-3-yl)-1-piperIdinyl]etyl]-1,3-dimetyl-lH-purin-2,6-dion metansulfonat; smeltepunkt 243, 1°C, (forbindelse 25).
Eksempel 9
Til en omrørt oppløsning av 5 deler 3,7-dihydro-7-[2-<4->(1H-indol-3-yl )-1-piperidinyletyl]-1,3-dimetyl-lH-purin-2,6-dion I 160 deler 2-propanol og en liten mengde N,N-dimetyl formamid ble det tilsatt en oppløsning av 3,5 deler (+)-2,3-dihydroksybutandionsyre i metanol. Det hele ble omrørt i 30 minutter under tilbakeløp. Etter avkjøling ble produktet filtrert av og tørket og man oppnådde 6,5 deler (97,3%) av (+ )-3 , 7-dihydro-7-[2-[4-(lH-indol-3-yl)-1-piperidinyl]etyl]-1,3-dimetyl-lH-purin-2,6-dion [R-R<*>,R<*>)]-2,3-dihydroksy-butandioat(l:1 )R 64,488; smeltepunkt 218,2°C (forbindelse 26).
Ved å følge de samme prosedyrer og ved å bruke de egnede syrer ble det også fremstilt: 3 ,7-dihydro-7-[2-[4-( 1H-indol-3-yl )-l-piperdinyl]etyl]-1,3-dimetyl-lH-purin-2,6-dion (Z )-2-butendioat(1:1); smeltepunkt 166,9°C (forbindelse 27).
Claims (1)
1.
Analoglfremgangsmåte for fremstilling av terapeutisk aktive lH-indol-3-yl holdige 1,3-dimetyl-lH-purin-2,6-dioner med formelen
eller et farmasøytisk akseptabelt syreaddisjonssalt derav, hvori
Alk betyr en toverdig lavere alkylrest;
R er hydrogen, lavere alkyl, halogen, lavere alkyloksy eller hydroksy; og
den stiplede linje antyder at dobbeltbindingen mellom 3- og 4-karbonatomene i piperidinkjernen er eventuell, karakterisert ved å omsette mellomproduktet med formel
der Alk er som angitt ovenfor og W er en reaktiv avspaltbar gruppe og fortrinnsvis halogen, med et piperidin med formelen Analogifremgangsmåte ifølge krav 1 for fremstilling av 7[2-[4-(lH-indol-3-yl )-l-piperidinyl]-etyl]-3,7-dihydro-l,3-dimetyl-lH-purin-2,6-dion eller et farmasøytisk akseptabelt syreaddisjonssalt derav,
karakterisert ved at tilsvarende utgangs-materialer anvendes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/656,561 US4548939A (en) | 1984-10-01 | 1984-10-01 | 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones |
Publications (3)
Publication Number | Publication Date |
---|---|
NO853856L NO853856L (no) | 1986-04-02 |
NO162069B true NO162069B (no) | 1989-07-24 |
NO162069C NO162069C (no) | 1989-11-01 |
Family
ID=24633577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO853856A NO162069C (no) | 1984-10-01 | 1985-09-30 | Analogifremgangsmaate for fremstilling av 1h-indol-3-yl inneholdende 1,3-di-metyl-1h-purin-2,6-dioner. |
Country Status (17)
Country | Link |
---|---|
US (1) | US4548939A (no) |
EP (1) | EP0177087B1 (no) |
JP (1) | JPH0653742B2 (no) |
CN (1) | CN1011311B (no) |
AT (1) | ATE60604T1 (no) |
AU (1) | AU576386B2 (no) |
CA (1) | CA1262348A (no) |
DE (1) | DE3581577D1 (no) |
DK (1) | DK163996C (no) |
ES (1) | ES8609324A1 (no) |
FI (1) | FI83220C (no) |
GR (1) | GR852375B (no) |
IE (1) | IE58747B1 (no) |
NO (1) | NO162069C (no) |
NZ (1) | NZ213498A (no) |
PT (1) | PT81229B (no) |
ZA (1) | ZA857553B (no) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH648559A5 (de) * | 1981-07-20 | 1985-03-29 | Siegfried Ag | Theophyllinderivate und verfahren zu deren herstellung. |
US4742057A (en) * | 1985-12-05 | 1988-05-03 | Fujisawa Pharmaceutical Co., Ltd. | Antiallergic thiazole compounds |
KR0131327B1 (en) * | 1987-08-13 | 1998-04-17 | Glaxo Group Ltd | Indole derivatives |
GB8719167D0 (en) * | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
DK733788A (da) * | 1988-01-14 | 1989-07-15 | Fujisawa Pharmaceutical Co | Indolylpiperidinderivater og fremgangsmaade til fremstilling deraf |
GB8819024D0 (en) * | 1988-08-10 | 1988-09-14 | Glaxo Group Ltd | Chemical compounds |
DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
DK292A (da) * | 1991-11-29 | 1992-01-02 | Tanisake Kk | Middel |
DE4414113A1 (de) * | 1994-04-22 | 1995-10-26 | Merck Patent Gmbh | 3-Indolylpiperidine |
SI3184527T1 (sl) * | 2007-06-22 | 2020-03-31 | Eli Lilly And Company | Spojine 2,6-diokso,-2,3-dihidro-1H-purina uporabne za zdravljenje stanj povezanih z aktivnostjo TRPA1 kanala |
WO2010039289A2 (en) | 2008-05-14 | 2010-04-08 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
WO2009140517A1 (en) | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2322470A1 (de) * | 1973-05-04 | 1974-11-21 | Boehringer Sohn Ingelheim | Neue indolyl-piperidino-(bzw. 1,2,5,6tetrahydro-pyridyl-)butyrophenone und verfahren zu ihrer herstellung |
FR2334358A1 (fr) * | 1975-12-12 | 1977-07-08 | Sogeras | Nouveaux medicaments derives de l'indole |
FR2362628A1 (fr) * | 1976-08-26 | 1978-03-24 | Roussel Uclaf | Nouveaux derives du piperidyl-indole et leurs sels, procede de preparation et application a titre de medicaments |
EP0011399A1 (en) * | 1978-11-11 | 1980-05-28 | FISONS plc | N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them |
DE2922159A1 (de) * | 1979-05-31 | 1980-12-04 | Boehringer Mannheim Gmbh | Neue xanthin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US4342870A (en) * | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
US4426383A (en) * | 1980-09-04 | 1984-01-17 | Eisai Co., Ltd. | Theophylline and theobromine derivatives |
US4359468A (en) * | 1981-02-25 | 1982-11-16 | Boehringer Ingelheim Ltd. | Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones |
US4443451A (en) * | 1981-07-15 | 1984-04-17 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidin-5-one derivatives |
CH648559A5 (de) * | 1981-07-20 | 1985-03-29 | Siegfried Ag | Theophyllinderivate und verfahren zu deren herstellung. |
-
1984
- 1984-10-01 US US06/656,561 patent/US4548939A/en not_active Expired - Fee Related
-
1985
- 1985-07-30 CN CN85105804A patent/CN1011311B/zh not_active Expired
- 1985-09-10 CA CA000490317A patent/CA1262348A/en not_active Expired
- 1985-09-16 NZ NZ213498A patent/NZ213498A/en unknown
- 1985-09-18 DE DE8585201484T patent/DE3581577D1/de not_active Expired - Fee Related
- 1985-09-18 EP EP85201484A patent/EP0177087B1/en not_active Expired - Lifetime
- 1985-09-18 AT AT85201484T patent/ATE60604T1/de not_active IP Right Cessation
- 1985-09-27 JP JP60212731A patent/JPH0653742B2/ja not_active Expired - Lifetime
- 1985-09-30 GR GR852375A patent/GR852375B/el unknown
- 1985-09-30 ZA ZA857553A patent/ZA857553B/xx unknown
- 1985-09-30 DK DK444085A patent/DK163996C/da not_active IP Right Cessation
- 1985-09-30 NO NO853856A patent/NO162069C/no unknown
- 1985-09-30 IE IE240385A patent/IE58747B1/en not_active IP Right Cessation
- 1985-09-30 AU AU48124/85A patent/AU576386B2/en not_active Ceased
- 1985-09-30 FI FI853763A patent/FI83220C/fi not_active IP Right Cessation
- 1985-09-30 ES ES547447A patent/ES8609324A1/es not_active Expired
- 1985-10-01 PT PT81229A patent/PT81229B/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES547447A0 (es) | 1986-07-16 |
US4548939A (en) | 1985-10-22 |
EP0177087A3 (en) | 1986-06-11 |
AU4812485A (en) | 1986-04-10 |
JPS6187681A (ja) | 1986-05-06 |
NO853856L (no) | 1986-04-02 |
GR852375B (no) | 1986-01-31 |
DK163996B (da) | 1992-04-27 |
EP0177087B1 (en) | 1991-01-30 |
CN85105804A (zh) | 1986-10-22 |
NO162069C (no) | 1989-11-01 |
NZ213498A (en) | 1988-04-29 |
FI83220B (fi) | 1991-02-28 |
PT81229A (en) | 1985-11-01 |
DK163996C (da) | 1992-09-21 |
FI853763L (fi) | 1986-04-02 |
DK444085A (da) | 1986-04-02 |
ZA857553B (en) | 1987-05-27 |
AU576386B2 (en) | 1988-08-25 |
IE852403L (en) | 1986-04-01 |
EP0177087A2 (en) | 1986-04-09 |
ATE60604T1 (de) | 1991-02-15 |
IE58747B1 (en) | 1993-11-03 |
JPH0653742B2 (ja) | 1994-07-20 |
CA1262348A (en) | 1989-10-17 |
PT81229B (pt) | 1987-11-30 |
CN1011311B (zh) | 1991-01-23 |
DE3581577D1 (de) | 1991-03-07 |
FI83220C (fi) | 1991-06-10 |
DK444085D0 (da) | 1985-09-30 |
FI853763A0 (fi) | 1985-09-30 |
ES8609324A1 (es) | 1986-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK169073B1 (da) | (4-piperidinylmethyl og -hetero)puriner, præparater indeholdende disse samt fremgangsmåde til fremstilling af disse purinforbindelser | |
FI71737B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3-(piperidinylalkyl)-4h-pyrido/1,2-a/ pyrimidin-4-on-derivat | |
IE58388B1 (en) | 1,2-benzisoxazol -3-yl and 1,2-benzisothiazol-3-yl derivatives | |
DK160314B (da) | Analogifremgangsmaade til fremstilling af bicycliske pyrimidin-5-on-derivater og farmaceutisk acceptable salte deraf | |
US5001130A (en) | Psychotropic heterobicycloalkylpiperazine derivatives | |
NO162069B (no) | Analogifremgangsm te for fremstilling av 1h-indol-3-yl inneholdende 1,3-di-metyl-1h-purin-2,6-dioner. | |
WO2009065920A2 (de) | Verbindungen | |
CZ281114B6 (cs) | N-Heterocyklyl-4-piperidinaminy, způsob jejich přípravy a antialergický přípravek na jejich bázi | |
FI94526B (fi) | Menetelmä terapeuttisesti käyttökelpoisten bentsimidatsol-2-yyli- ja imidatso/4,5-b/pyridin-2-yyli-amino- ja -metyyli-1-piperidinyylietyylijohdannaisten valmistamiseksi | |
EP2906221A1 (en) | Urea and amide derivatives of aminoalkylpiperazines and use thereof | |
KR100206723B1 (ko) | 신규 치환된 티아졸릴 및 치환된 피리디닐 유도체 | |
SK278133B6 (en) | Oxazole derivatives method of their production and antialergic preparations on their base | |
DK175124B1 (da) | 3-piperazinylbenzazolderivater, fremstilling deraf og anvendelse deraf i et antipsykotisk præparat | |
CA2210913C (en) | Antipsychotic 4-(1h-indolyl-1-yl)-1-substituted piperidine derivatives | |
PL189549B1 (pl) | Pochodna 1,2,3,4-tetrahydro-benzofuro [3,2-c] pirydyny, jej zastosowanie, kompozycja farmaceutycznai sposób wytwarzania pochodnej 1,2,3,4-tetrahydro-benzofuro [3,2-c] pirydyny | |
FI81800B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,2-bensisoxazol-3-yl-1-piperidinylalkylpyridopyrimidinon- och -tiazolopyrimidinonderivat. | |
DK169547B1 (da) | 3-piperidinyl-indazolderivater, fremgangsmåde til fremstilling deraf, præparater indeholdende disse samt anvendelse af derivaterne til fremstilling af farmaceutiske præparater | |
US5116970A (en) | Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones |